Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.

ABSTRACT: Rhenium tricarbonyl complexes have been recently investigated as novel anticancer agents. However, little is understood about their mechanisms of action, as well as the means by which cancer cells respond to chronic exposure to these compounds. To gain a deeper mechanistic insight into these rhenium anticancer agents, we developed and characterized an ovarian cancer cell line that is resistant to a previously studied compound [Re(CO)₃ (dmphen)(ptolICN)]⁺ , where dmphen=2,9-dimethyl-1,10-phenanthroline and ptolICN=para-tolyl isonitrile, called TRIP. This TRIP-resistant ovarian cancer cell line, A2780TR, was found to be 9 times less sensitive to TRIP compared to the wild-type A2780 ovarian cancer cell line. Furthermore, the cytotoxicities of established drugs and other

SUBMITTER: Marker SC 

PROVIDER: S-EPMC7482417 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature